WO2003087830A3 - Timp-1 as a postoperative marker for recurrent cancer - Google Patents

Timp-1 as a postoperative marker for recurrent cancer Download PDF

Info

Publication number
WO2003087830A3
WO2003087830A3 PCT/DK2003/000230 DK0300230W WO03087830A3 WO 2003087830 A3 WO2003087830 A3 WO 2003087830A3 DK 0300230 W DK0300230 W DK 0300230W WO 03087830 A3 WO03087830 A3 WO 03087830A3
Authority
WO
WIPO (PCT)
Prior art keywords
timp
postoperative
marker
recurrent cancer
individual
Prior art date
Application number
PCT/DK2003/000230
Other languages
French (fr)
Other versions
WO2003087830A2 (en
Inventor
Mads Holten-Andersen
Ib Jarle Christensen
Nils Bruenner
Hans Joergen Nielsen
Original Assignee
Rigshospitalet
Hvidovre Hospital
Mads Holten-Andersen
Ib Jarle Christensen
Nils Bruenner
Hans Joergen Nielsen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rigshospitalet, Hvidovre Hospital, Mads Holten-Andersen, Ib Jarle Christensen, Nils Bruenner, Hans Joergen Nielsen filed Critical Rigshospitalet
Priority to AU2003226925A priority Critical patent/AU2003226925A1/en
Publication of WO2003087830A2 publication Critical patent/WO2003087830A2/en
Publication of WO2003087830A3 publication Critical patent/WO2003087830A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/8146—Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP

Abstract

The present invention describes a method for determining whether an individual is suffering from minimal residual diseases or recurrent cancer during treatment and/or after being treated for the primary cancer by determining a parameter representing the post-operative TIMP-1 concentration in body fluid samples from the individual. In addition, the invention describes the additive effect of combined post-operative measurements of plasma TIMP-1 and serum CEA.
PCT/DK2003/000230 2002-04-08 2003-04-08 Timp-1 as a postoperative marker for recurrent cancer WO2003087830A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003226925A AU2003226925A1 (en) 2002-04-08 2003-04-08 Timp-1 as a postoperative marker for recurrent cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200200510 2002-04-08
DKPA200200510 2002-04-08

Publications (2)

Publication Number Publication Date
WO2003087830A2 WO2003087830A2 (en) 2003-10-23
WO2003087830A3 true WO2003087830A3 (en) 2003-12-31

Family

ID=29225532

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2003/000230 WO2003087830A2 (en) 2002-04-08 2003-04-08 Timp-1 as a postoperative marker for recurrent cancer

Country Status (2)

Country Link
AU (1) AU2003226925A1 (en)
WO (1) WO2003087830A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7374886B2 (en) 1999-04-09 2008-05-20 Rigshospitalet Tissue inhibitor of matrix metalloproteinases type-1 (TIMP-1) as a cancer marker and postoperative marker for minimal residual disease or recurrent disease in patients with a prior history of cancer
EP1619206A3 (en) 1999-04-09 2006-02-15 Rigshospitalet Tissue inhibitor of matrix metallproteinases type-1 (TIMP-1) as a cancer marker
CN1685235A (en) 2002-09-26 2005-10-19 里格舒斯匹塔里特医院 A method for detecting, screening and/or monitoring a cancer in an individual
US7943328B1 (en) 2006-03-03 2011-05-17 Prometheus Laboratories Inc. Method and system for assisting in diagnosing irritable bowel syndrome
US20080085524A1 (en) 2006-08-15 2008-04-10 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
US8697384B2 (en) 2008-01-23 2014-04-15 Herlev Hospital YKL-40 as a general marker for non-specific disease
NZ592241A (en) 2008-09-15 2012-11-30 Herlev Hospital Ykl-40 as a marker for gastrointestinal cancers
US20130210645A1 (en) * 2010-02-18 2013-08-15 The Johns Hopkins University Personalized tumor biomarkers

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000062070A2 (en) * 1999-04-09 2000-10-19 Rigshospitalet Tissue inhibitor of matrix metalloproteinases type-1 (timp-1) as a cancer marker

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000062070A2 (en) * 1999-04-09 2000-10-19 Rigshospitalet Tissue inhibitor of matrix metalloproteinases type-1 (timp-1) as a cancer marker

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CANCER EPIDEMIOLOGY, BIOMARKERS & PREVENTION: A PUBLICATION OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, COSPONSORED BY THE AMERICAN SOCIETY OF PREVENTIVE ONCOLOGY. UNITED STATES FEB 1998, vol. 7, no. 2, February 1998 (1998-02-01), pages 109 - 112, ISSN: 1055-9965 *
DATABASE MEDLINE [online] February 1998 (1998-02-01), ZHOU W ET AL: "Identifying markers for pancreatic cancer by gene expression analysis.", XP002253492, Database accession no. NLM9488584 *
HOLTEN-ANDERSEN MADS N ET AL: "Plasma levels of Tissue Inhibitor of Metalloproteinases 1 measured during follow-up of colorectal cancer patients have clinical value in predicting patient outcome.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL, vol. 43, March 2002 (2002-03-01), 93rd Annual Meeting of the American Association for Cancer Research;San Francisco, California, USA; April 06-10, 2002, March, 2002, pages 715, XP002253488, ISSN: 0197-016X *
HOLTEN-ANDERSEN MADS N ET AL: "Total levels of tissue inhibitor of metalloproteinases 1 in plasma yield high diagnostic sensitivity and specificity in patients with colon cancer.", CLINICAL CANCER RESEARCH: AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. UNITED STATES JAN 2002, vol. 8, no. 1, January 2002 (2002-01-01), pages 156 - 164, XP002253491, ISSN: 1078-0432 *
TAKADA N ET AL: "Postoperative sequential changes of serum levels of matrix metalloproteinase and tissue inhibitor of metalloproteinase in Japanese patients with the squamous cell carcinoma of esophagus.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL, vol. 40, March 1999 (1999-03-01), 90th Annual Meeting of the American Association for Cancer Research;Philadelphia, Pennsylvania, USA; April 10-14, 1999, March, 1999, pages 346, XP002253489, ISSN: 0197-016X *
ZUCKER STANLEY ET AL: "Plasma assay of gelatinase B: Tissue inhibitor of metalloproteinase complexes in cancer.", CANCER (PHILADELPHIA), vol. 76, no. 4, 1995, pages 700 - 708, XP002253490, ISSN: 0008-543X *

Also Published As

Publication number Publication date
WO2003087830A2 (en) 2003-10-23
AU2003226925A1 (en) 2003-10-27
AU2003226925A8 (en) 2003-10-27

Similar Documents

Publication Publication Date Title
WO2005117938A3 (en) Methods of treating ocular conditions
EP1619206A3 (en) Tissue inhibitor of matrix metallproteinases type-1 (TIMP-1) as a cancer marker
TW200716673A (en) Use of TNF &ahr; inhibitor for treatment of erosive polyarthritis
WO2003101444A8 (en) Diarylurea compounds and derivatives as chk-1 inhibitors for the treatment of cancer
WO2002030353A3 (en) NF-λB INHIBITORS
WO2003073999A3 (en) Pini-modulating compounds and methods of use thereof
WO2008063213A3 (en) Uses and compositions for treatment of psoriatic arthritis
WO2004009776A3 (en) TREATMENT OF TNFα RELATED DISORDERS
TW200528117A (en) Methods and reagents for the treatment of proliferative diseases
WO2003074550A3 (en) Pin1-modulating compounds and methods of use thereof
WO2008140774A3 (en) Methods for diagnosing and treating prostate and lung cancer
WO2003089904A3 (en) Aib1 as a prognostic marker and predictor of resistance to encocrine therapy
WO2004010937A3 (en) Method of treating cancer
WO2001044247A3 (en) Agents and methods for the treatment of proliferative diseases
AU2003233451A1 (en) Targets, methods, and reagents for diagnosis and treatment of schizophrenia
WO2005117846A3 (en) Ice inhibitors for the treatment of autoinflammatory diseases
WO2006001931A3 (en) Prouroguanylin as therapeutic and diagnostic agents
WO2004032882A3 (en) Chemical compounds
AU2002365166A1 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of rheumatoid arthritis
WO2003087830A3 (en) Timp-1 as a postoperative marker for recurrent cancer
WO2004033666A3 (en) Method and compounds for inhibiting hec1 activity for the treatment of proliferative diseases
WO2005007123A3 (en) Pin1-modulating compounds and methods of use thereof
WO2002039122A3 (en) Methods for the identification and the treatment of cardiovascular disease
WO2003073821A3 (en) Shc PROTEIN-RELATED METHODS AND COMPOSITIONS FOR THE PROGNOSIS OF BREAST, PROSTATE AND OVARIAN CANCER
WO2004046182A3 (en) Use of soluble forms of cd83 and nucleic acids encoding them for the treatment or prevention of diseases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP